Sebastien Bolze

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Journal: Journal of hepatology

Published: November 24, 2022

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.

Journal: Endocrinology, diabetes & metabolism

Published: July 11, 2022

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.

Journal: The Journal of pharmacology and experimental therapeutics

Published: March 14, 2022

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

Journal: Physiological reports

Published: November 29, 2021

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.

Journal: Clinical and translational science

Published: August 20, 2021

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Journal: The lancet. Gastroenterology & hepatology

Published: June 21, 2021

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Journal: Cell reports. Medicine

Published: May 31, 2021

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.

Journal: Hepatology communications

Published: April 02, 2021

Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity.

Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity.

Journal: Hepatology communications

Published: December 11, 2020

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.

Journal: PloS one

Published: October 13, 2020

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.

Journal: Clinical pharmacokinetics

Published: October 04, 2020

Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.

Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.

Journal: Endocrinology, diabetes & metabolism

Published: August 22, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026